Immuno-Oncology Investing & Partnering Forum's Participating Companies
View the Immuno-Oncology Investing & Partnering Forum's agenda here!
Learn more about 1 on 1 Partnering with our Online Planner
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.
Investing since 2009, AbbVie Ventures focuses exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Aligning with AbbVie’s strategic focus, our investments address critical needs in oncology, immunology, and neuroscience. We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful. Targeting 6-8 new investments annually, at the Seed or Series A stage, we have the capability and flexibility to lead or co-lead a syndicate. Our team of eight investing professionals is based in three locations: Boston, San Francisco and Chicago areas.
Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors.
Atlas Venture is a leading biotech venture capital firm. Atlas has been building breakthrough biotech startups for over 25 years, working side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients.
Antigen Express, a Wholly-owned Subsidiary of Generex Biotechnology is an immuno-oncology company developing immunotherapy & vaccine formulations based upon proprietary Ii- Key hybrid peptides that activate the immune system through MHC Class I and Class II activation. The company has a pipeline of immunotherapeutics, including an ongoing clinical development program to evaluate the use of AE37, a HER-2/neu directed immunotherapeutic vaccine that has shown preliminary efficacy in triple-negative breast cancer.
Immunotherapy Foundation (IF) is dedicated to eradicating HPV-related cancers by catalyzing immunotherapy research and advancing the HPV vaccine as a critical cancer prevention tool. From inception, IF has strategically supported the most promising cancer immunotherapy research for HPV-driven cancers, working directly with world-class researchers to accelerate discovery and development. The projects are tightly interconnected to leverage information and hold promise to extend to other malignancies. In 2017, to comprehensively address the HPV-related cancer burden, IF expanded its scope to include educational programming and advocacy for the HPV vaccine. Through collaborative partnerships, IF is working to amplify existing education and advocacy initiatives, and build out regional, national, and international efforts to reduce incidence of HPV-related cancers.
INmune Bio Inc. iis a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Our drug candidates, INKmune and INB03, can be used alone or with conventional therapies to help eliminate disease in a wide variety of cancers. They can also boost the effectiveness of other immunotherapies designed to enhance immune response to specific tumors.
The development of new immunotherapies is revolutionizing cancer care. INmune Bio is at the forefront of that revolution with novel products that take the brakes off of the most powerful weapon in the fight against cancer: the patient’s immune system.
Merck is a leading global biopharmaceutical company that has been inventing for life for more than a century, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
MPM Capital is a venture firm founding and investing in early-stage life sciences companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders and regenerative medicine. With its experienced and dedicated investment team, executive partners and entrepreneurs, and its medical and scientific advisory board, MPM is powering novel medical breakthroughs that transform patients’ lives. MPM is currently investing from its BV2014 and BV2018 funds. It also invests from the UBS Oncology Impact Fund managed by MPM -- the first-of-its-kind, oncology-only social impact fund that donates a portion of its profits and royalties to cancer research and cancer care. For further information, please visit www.mpmcapital.com.
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies. By leveraging both vaccines and T cell therapies, we hope to offer a new level of patient and tumor specificity that will drive a strong risk-benefit profile to improve patient outcomes.
Novartis has a clear mission, focused strategy and strong culture, all of which we expect will support the creation of value over the long term for our company, our shareholders and society.
Our strategy is to use science-based innovation to deliver better patient outcomes in growing areas of healthcare.
We believe innovation that produces breakthrough medicines and products will be more important than ever in the healthcare industry in the coming years. We maintain substantial investment in research and development (R&D) aimed at areas of unmet medical need. Our product pipeline is fed by a research and development approach that uses the latest science to advance the most promising projects.
The Parker Institute for Cancer Immunotherapy brings together the top scientists, clinicians and industry partners to build a smarter, more coordinated cancer immunotherapy research effort. The institute fuels ambitious research with innovative services, tools and resources to accelerate discoveries and get treatments to patients faster. Visit www.parkerici.org to learn more.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Siva Therapeutics is developing a cancer treatment which promises to be minimally invasive, to reduce harmful side effects, and to stimulate the immune system. In addition to being more affordable, this technology could deliver faster results than current cancer treatments. Siva achieves this treatment, termed Targeted Hyperthermia™, using SivaRod™ gold nanorods and a SivaLum™ infrared light device, which generates therapeutic heat emanating from within solid tumors.
Founded in 1974, Sofinnova is a clinical-stage biopharmaceutical venture capital firm with approximately $2.2B under management. We are a passionate and committed team of MDs and PhDs that deploy human and financial capital to improve the lives of patients through science. Our mission is to provide industry leading venture returns by delivering transformative medicines to patients. We live our mission to deliver outstanding results for those we serve – patients, entrepreneurs, and the people and organizations that entrust us with their capital.